Last $6.75 USD
Change Today -0.05 / -0.74%
Volume 1.8M
ARWR On Other Exchanges
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

arrowhead research corp (ARWR) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $27.63
52 Week Low
10/8/14 - $5.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

arrowhead research corp (ARWR) Related Businessweek News

No Related Businessweek News Found

arrowhead research corp (ARWR) Details

Arrowhead Research Corporation, a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. The company’s product candidate comprise ARC-520, an RNAi-based therapeutic that has completed a Phase 1 clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and Adipotide, which is in Phase I clinical trial for the treatment for obesity and related metabolic disorders. Its platform technologies include Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown, and induces endosomal escape; and Homing Peptides platform, a library of short peptides. The company also develops DPC-enabled RNAi therapeutic, a pre-clinical stage product to treat an undisclosed orphan liver disease. It also has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.

54 Employees
Last Reported Date: 12/18/13
Founded in 2003

arrowhead research corp (ARWR) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $579.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $305.1K
Chief Operating Officer and Head of R&D
Total Annual Compensation: $417.5K
Compensation as of Fiscal Year 2013.

arrowhead research corp (ARWR) Key Developments

Levi & Korsinsky, LLP Files Class Action against Arrowhead Research Corp

Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Arrowhead Research Corp. stock between August 12, 2014 and October 8, 2014. The complaint alleges that Arrowhead Research materially misstated clinical trial information from its experimental hepatitis B therapy ARC-520 by falsely suggesting that the therapy was more effective than it actually was.

Arrowhead Research Corporation Presents ARC-520 Phase 2a Data in Late-Breaking Session at AASLD Liver Meeting 2014

Arrowhead Research Corporation announced that data from the ongoing Phase 2a study of ARC-520, its RNAi therapeutic candidate for the treatment of chronic hepatitis B (HBV) infection, will be presented in the late-breaking poster session at the 2014 American Association for the Study of Liver Diseases (AASLD) Liver Meeting being held on November 7-11, 2014, in Boston. Arrowhead was also selected to deliver a plenary presentation with new preclinical efficacy data on ARC-AAT, its RNAi therapeutic candidate for the treatment of liver disease associated with Alpha-1 antitrypsin deficiency.

Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs

Arrowhead Research Corporation announced that Susan Boynton has been appointed Vice President, Global Regulatory Affairs. In this role, Ms. Boynton will have overall leadership responsibilities to direct the Company's regulatory initiatives and strategy, and to ensure appropriate regulatory compliance in the conduct of all Arrowhead development programs and required reporting to the FDA and international health authorities. Susan Boynton is an accomplished regulatory affairs professional with 30 years of experience developing successful regulatory strategies, leading global filings, and ensuring regulatory compliance in the U.S., EU, and other major markets.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARWR:US $6.75 USD -0.05

ARWR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ARWR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ARWR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2,017.9x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,126.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARROWHEAD RESEARCH CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at